In vivo test systems for the quantitative and qualitative analysis of the biological activity of phytoestrogens

被引:51
作者
Diel, P [1 ]
Schmidt, S
Vollmer, G
机构
[1] Deutsch Sporthsch, Inst Morphol & Canc Res, D-50927 Cologne, Germany
[2] Tech Univ Dresden, Inst Zool Mol Cell Physiol & Endocrinol, D-01062 Dresden, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 777卷 / 1-2期
关键词
reviews; uterotrophic assay; in vivo test systems; phytoestrogens;
D O I
10.1016/S1570-0232(02)00494-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Many compounds of plant origin with the ability to bind to the estrogen receptor have been identified in the last decades. One of the most extensively used in vivo assays to characterise the estrogenic potency of these phytoestrogens and mechanisms of their action is the rodent uterotrophic assay. Various protocols exist for this test system, using immature, hypophysectomized, or ovariectomized rats and mice and oral or subcutaneous administration of the test compound. However, just monitoring the ability of a compound to stimulate uterine growth is not sufficient to characterize its estrogenicity. Over the last decades, an increasing number of estrogen sensitive tissues has been identified. Moreover, a variety of different molecular mechanisms have been discovered for the action of estrogens, including non-genomic actions. Therefore, an in vivo test design for estrogenicity should include an analysis of several estrogen sensitive parameters in different estrogen sensitive tissues. To distinguish between agonistic and antagonistic properties of a substance, combinations of the test compound with estrogens and antiestrogens should be analyzed. A reasonable supplement to this enhanced uterotrophic assay are selected estrogen sensitive tumor models, which can be used to test for potential chemopreventive properties of phytoestrogens. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 202
页数:12
相关论文
共 82 条
[1]  
ADLERCREUTZ H, 1982, LANCET, V2, P1295
[2]   DIETARY PHYTOESTROGENS AND CANCER - INVITRO AND INVIVO STUDIES [J].
ADLERCREUTZ, H ;
MOUSAVI, Y ;
CLARK, J ;
HOCKERSTEDT, K ;
HAMALAINEN, E ;
WAHALA, K ;
MAKELA, T ;
HASE, T .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 41 (3-8) :331-337
[3]  
Adlercreutz H., 1988, Progress in diet and nutrition, P165
[4]  
Allred CD, 2001, CANCER RES, V61, P5045
[5]   Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones [J].
Aronson, WJ ;
Tymchuk, CN ;
Elashoff, RM ;
McBride, WH ;
McLean, C ;
Wang, HJ ;
Heber, D .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 35 (02) :130-136
[6]   The chemopreventive properties of soy isoflavonoids in animal models of breast cancer [J].
Barnes, S .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 46 (2-3) :169-179
[7]   Comparison between different cell kinetic variables in human breast cancer [J].
Barzanti, F ;
Dal Susino, M ;
Volpi, A ;
Amadori, D ;
Riccobon, A ;
Scarpi, E ;
Medri, L ;
Bernardi, L ;
Naldi, S ;
Aldi, M ;
Gaudio, M ;
Zoli, W .
CELL PROLIFERATION, 2000, 33 (02) :75-89
[8]   RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS [J].
BLACK, LJ ;
SATO, M ;
ROWLEY, ER ;
MAGEE, DE ;
BEKELE, A ;
WILLIAMS, DC ;
CULLINAN, GJ ;
BENDELE, R ;
KAUFFMAN, RF ;
BENSCH, WR ;
FROLIK, CA ;
TERMINE, JD ;
BRYANT, HU .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :63-69
[9]  
Bylund A, 2000, PROSTATE, V42, P304, DOI 10.1002/(SICI)1097-0045(20000301)42:4<304::AID-PROS8>3.0.CO
[10]  
2-Z